Actively Recruiting
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
Led by The Christie NHS Foundation Trust · Updated on 2025-09-05
60
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.
CONDITIONS
Official Title
A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- No contraindications to MRI
- Eligible for abdominal SABR per NHSE SABR Consortium Guidelines or central lung SABR per RTOG Guidelines
- Able to provide informed consent
- Anticipated life expectancy greater than 6 months
- No more than 3 oligometastatic sites treated in total
- Performance status of 2 or less
- Willing to attend follow-up visits and have data collected for at least 1 year
You will not qualify if you...
- Any contraindications to MRI identified after safety screening
- Unable to tolerate MRI scans
- Severe or uncontrolled systemic diseases making participation undesirable
- Significant clinical disorders or lab findings making participation undesirable
- Known active hepatitis B, hepatitis C, or HIV infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Christie NHS Foundation Trust
Manchester, United Kingdom, United Kingdom, M204BX
Actively Recruiting
Research Team
C
Clare Griffin
CONTACT
C
Cynthia Eccles
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here